Media headlines about Fluidigm (NASDAQ:FLDM) have trended positive this week, Accern reports. The research group identifies negative and positive media coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Fluidigm earned a news impact score of 0.27 on Accern’s scale. Accern also gave news stories about the medical research company an impact score of 44.8576539507392 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
Shares of Fluidigm stock traded up $0.14 during midday trading on Thursday, reaching $6.06. The company had a trading volume of 114,535 shares, compared to its average volume of 213,682. The company has a debt-to-equity ratio of 6.31, a current ratio of 2.83 and a quick ratio of 2.38. The firm has a market cap of $218.90, a P/E ratio of -5.09 and a beta of 2.99. Fluidigm has a 1-year low of $2.52 and a 1-year high of $8.38.
Fluidigm (NASDAQ:FLDM) last issued its quarterly earnings results on Thursday, February 8th. The medical research company reported ($0.27) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.02). Fluidigm had a negative net margin of 59.38% and a negative return on equity of 118.56%. The company had revenue of $27.75 million during the quarter, compared to analyst estimates of $27.14 million. During the same period in the prior year, the business earned ($0.32) EPS. The business’s revenue for the quarter was up 10.6% on a year-over-year basis. sell-side analysts expect that Fluidigm will post -0.93 EPS for the current year.
In other Fluidigm news, insider Levin Capital Strategies, L.P. acquired 6,871 shares of Fluidigm stock in a transaction on Tuesday, January 23rd. The shares were purchased at an average cost of $6.57 per share, with a total value of $45,142.47. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Over the last ninety days, insiders acquired 723,607 shares of company stock worth $4,498,707. Insiders own 4.70% of the company’s stock.
Fluidigm Company Profile
Fluidigm Corporation creates, manufactures and markets technologies and life science tools focused on the exploration and analysis of single cells, as well as the industrial application of genomics, based upon the Company’s core microfluidics and mass cytometry technologies. The Company operates in the development, manufacturing and commercialization of life science tools for the life science and Ag-Bio industries segment.
Receive News & Ratings for Fluidigm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fluidigm and related companies with MarketBeat.com's FREE daily email newsletter.